Abstract
The traditional Chinese herb Anoectochilus roxburghii (A. roxburghii) is well-known for its medicinal value, but few studies have reported its ability to combat metabolic syndrome activities in vitro. In this study, the extraction of seven compounds from A. roxburghii using 70% ethanol, RP-C18, thin layer chromatography (TLC), Sephadex LH-20, high performance liquid chromatography (HPLC) and subsequent identification of their structures through nuclear magnetic resonance (NMR). Among these compounds, kaempferol-3-O-rutinoside and isorhamnetin-3-O-α-l-rhamnopyranoside-7-O-β-d-glucopyranoside were obtained from A. roxburghii for the first time. Results showed that those compounds inhibited key enzymes involved in metabolic syndrome in vitro. Molecular docking and binding free energy calculations were employed to elucidate the inhibition mechanism of these compounds, while SwissADME was used to assess their drug-like characteristics. Notably, 9-hydroxy-megastigma-4,7-dien-3-one-9-O-β-d-glucopyranoside has the potential as an α-amylase inhibitor for the first time. This research enriches the compound library of A. roxburghii and provides new ideas for medication research and the development of metabolic syndrome.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.